Awards & Achievements
From incorporation to public validation - early evidence of traction across innovation, governance, IP and NHS-facing readiness.
Timeline of achievement
An evidence-led build phase moving quickly from incorporation to public milestones with a more credible pharmaceutical narrative.
NEUVIOR® incorporation
Founded NEUVIOR Pharmaceuticals Ltd in Glasgow.
Established a group structure spanning medicines intelligence, supply, research and pharmacy operations.
Innovate UK Growth Catalyst – New Innovators Award
Awarded for PHARMORIS™ - Generics Optimisation Platform for NHS and Global Health.
Public validation of the company’s medicines optimisation thesis at exceptional speed.
NHS DSPT Standards Met
Published for the 2025-26 cycle.
Strengthened readiness for NHS pilots, information governance scrutiny and early health-system engagement.
PHARMORIS® trade mark published
UK00004301201 published by the Intellectual Property Office.
Protected the PHARMORIS brand across software, AI, data analytics and pharmaceutical research service classes.
Patent filing initiated
IPO UK filing completed for core PHARMORIS architecture; PCT protection planned for 2026.
Signals intent to protect differentiated workflow and infrastructure design as the platform expands.
ZYLON™ feasibility programme
Innovate UK-backed work on AI-optimised solvent recovery and bio-intelligent materials.
Extends the group narrative beyond software into lower-waste pharmaceutical manufacturing R&D.
Recognition and validation
September 2025
Innovate UK Growth Catalyst – New Innovators Award
PHARMORIS™ - Generics Optimisation Platform for NHS and Global Health.
Awarded 39 days from incorporation, validating the company’s early product strategy and pace of execution.
29 November 2025
NHS DSPT Standards Met
2025-26 publication
Published on the NHS DSPT portal, supporting information governance credibility for NHS-facing conversations and pilots.
5 December 2025
PHARMORIS® trade mark published
UK00004301201
Formal publication by IPO UK across software and pharmaceutical research classes, reinforcing protection of the platform’s commercial identity.
Press Features & Ceremonies
Capturing moments of recognition, innovation showcases, and industry engagement
December 2025
UK Pharma Summit Keynote
Presenting ZYLON™ to industry leaders
September 2025
Innovate UK Growth Catalyst Award
January 2026
Press Conference
Upcoming milestones
The next phase focuses on pilots, assurance depth, supply infrastructure and durable commercial traction.
PHARMORIS® Commissioning pilot
Deploy the Discover / Justify / Deploy workflow for ICB and system medicines optimisation teams.
PHARMORIS® Provider pilot
Extend the same operating system into trusts, provider collaboratives and procurement-facing pharmacy leaders.
IP & assurance expansion
Advance PCT protection, strengthen governance artefacts and continue building enterprise-grade data assurance.
Strategic manufacturing and supply partnerships
Develop partnerships that connect PHARMORIS®, Rx, Labs and ZYLON™ into a broader pharmaceutical infrastructure model.
Follow our journey
Stay close to the next phase of NEUVIOR as pilots, partnerships and product infrastructure mature.
Investor relations
Discuss the group model, PHARMORIS revenue strategy, infrastructure roadmap and future adjacencies.
Press & media
Request briefings, founder commentary, milestone summaries and approved corporate materials.
NHS & strategic partnerships
Explore pilots, deployment conversations, pharmacy collaborations and medicines value programmes.